Drug Profile
Nitroglycerin-transdermal - Stowic
Latest Information Update: 19 Nov 2003
Price :
$50
*
At a glance
- Originator Stowic Resources
- Class
- Mechanism of Action Nitric oxide donors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Angina pectoris
Most Recent Events
- 19 Nov 2003 No development reported - Phase-I/II for Angina pectoris in United Kingdom (Transdermal)
- 18 Oct 2002 The assets of Stowic Resources have been acquired by United Pharmaceuticals
- 21 Nov 2001 Investigation in Angina pectoris in United Kingdom (Transdermal)